Reports have indicated that introducing RLN2 into cancer cells may suppress fibrosis within tumors by modulating macrophage polarization, thereby enhancing cytotoxic T cell infiltration and immune checkpoint inhibitor efficacy (53). The gene discussed is RLN2; the disease is cancer.